Supply Chain Council of European Union | Scceu.org
Supply Chain Risk

NHL trade deadline 2022: Live updates, rumors, picks and grades as Mark Giordano traded to Maple Leafs

Might as well start with the team that won the deal. Dumping the last year of Travis Hamonic’s deal, in any form, would’ve been a nice bit of business for the Jim Rutherford regime. Hamonic, at this point in his career, isn’t much more than a replacement-level defenseman, and he makes $3 million a season. That’s unnecessary for most teams, let alone one staring down cap issues and a decision on Brock Boeser’s $7.5 million qualifying offer.

This is a great way to start clearing the decks. If there’s a downside, it’s impossible to see. There’s no salary retained, no undesirable asset on the way back from Ottawa, and Hamonic, though he was a difference maker at times earlier in his career, isn’t an on-ice loss, especially for a team that won’t make the playoffs.

Ah, yes, “a team that won’t make the playoffs.” Time to talk about the Ottawa Senators. Adding Hamonic at all, let alone for a third-round pick, is nonsensical. They’re not good. They’re not going to be good. Giving up a half-decent asset for the right to overpay a player in decline? That’s not unprecedented, but it’s close enough.

What makes it funnier — unless you’re a Sens fan — is that it comes in concert with their failing negotiations with forward Nick Paul. Paul is a win-now role player with value somewhere — just not $3 million worth in Ottawa. With a good team, perhaps. In a vacuum, it makes sense that the Sens would play hardball with Paul. Why overextend ourselves on guys who aren’t difference-makers? Excuse us, it’s time to go close on a deal for Travis Hamonic. If they wanted to add a body, Phillippe Myers was just on waivers. No trade compensation necessary. It’d be incomprehensible if it were a different team.

Actually, wait a second; Hamonic was pretty good for Jack Capuano on Long Island, and Capuano is an assistant with the Sens. Maybe that’s why this happened.

Canucks: A+

Senators: F

Related posts

J.J. Watt, other Texans possibly on the chopping block with looming NFL trade deadline

scceu

BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia

scceu

In This Issue | PNAS

scceu